REXAHN PHARMACEUTICALS INC. DEF 14A 4-11-2017

Company

Opus Genetics, Inc.

Filed

February 24, 2017

Period of Report

April 11, 2017

Accession Number

0001140361-17-009142

A DEF 14A is a proxy statement sent to shareholders before an annual meeting. It covers executive compensation, board elections, and shareholder votes. Learn more about DEF 14A filings →